A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa
More than 2 pulmonary exacerbations requiring IV antibiotics within 12 months prior to screening
Receipt of antibiotics (excluding macrolides) within 30 days prior to screening
Clinically significant hemoptysis requiring intervention within 30 days prior to screening
Receiving anti-infective treatment for concurrent nontuberculosis mycobacteria (NTM) or fungal infection
Clareo Health | A Phase 1a/1b Study to Investigate the Safety, Tolerability, Microbiological Response, and Pharmacokinetics of Inhaled Rev-56 in Adult Healthy Volunteers and Adult Non-cystic Fibrosis Bronchiectasis (NCFB) Patients With Chronic P. Aeruginosa
